Article Text

Download PDFPDF
Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. YT had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

  • Funding This work was supported in part by a Research Grant-In-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the University of Occupational and Environmental Health, Japan.

  • Competing interests YT has received consulting fees, speaking fees and/or honoraria from Chugai Pharma, Mitsubishi-Tanabe Pharma, Eisai Pharma, Pfizer, Abbott Immunology Pharma, Janssen Pharma, Takeda Industrial Pharma, Astra-Zeneca, Astellas Pharma, Asahi-kasei Pharma and GlaxoSmithKline and has received research grant support from Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma, MSD, Takeda Industrial Pharma, Astellas Pharma, Eisai Pharma, Chugai Pharma, Pfizer and Daiichi-Sankyo. KS is employee of the Mitsubishi Tanabe Pharma Corporation.

  • Provenance and peer review Not commissioned; externally peer reviewed.